Halozyme Therapeutics (NASDAQ:HALO) Rating Lowered to “Buy” at Wall Street Zen

Halozyme Therapeutics (NASDAQ:HALO) was downgraded by equities research analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued on Saturday, Wall Street Zen reports.

A number of other analysts also recently issued reports on HALO. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Leerink Partners raised shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $83.00 to $110.00 in a research report on Friday, August 7th. Stifel Nicolaus set a $130.00 target price on Halozyme Therapeutics in a report on Friday, October 16th. TD Cowen increased their price objective on shares of Halozyme Therapeutics from $105.00 to $130.00 and gave the stock a “buy” rating in a research note on Tuesday, October 13th. Finally, JPMorgan Chase & Co. increased their price target on shares of Halozyme Therapeutics from $78.00 to $79.00 and gave the company a “neutral” rating in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $106.09.

Halozyme Therapeutics Trading Down 15.7%

NASDAQ HALO opened at $103.63 on Friday. The business’s fifty day moving average is $115.19 and its 200 day moving average is $84.73. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. The company has a market cap of $11.76 billion, a price-to-earnings ratio of 26.37, a price-to-earnings-growth ratio of 0.49 and a beta of 0.92. Halozyme Therapeutics has a twelve month low of $61.22 and a twelve month high of $134.00.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported $2.39 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.09. The business had revenue of $492.97 million during the quarter, compared to the consensus estimate of $491.63 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%. The firm’s revenue for the quarter was up 39.1% compared to the same quarter last year. During the same period in the prior year, the company posted $1.72 EPS. As a group, sell-side analysts expect that Halozyme Therapeutics will post 8.32 EPS for the current fiscal year.

Insider Buying and Selling

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $107.43, for a total value of $2,148,600.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at $82,482,605.40. The trade was a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $102.80, for a total value of $167,152.80. Following the transaction, the director owned 40,418 shares in the company, valued at $4,154,970.40. The trade was a 3.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 125,852 shares of company stock worth $13,538,046. Insiders own 2.50% of the company’s stock.

Hedge Funds Weigh In On Halozyme Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Bank of America Corp DE bought a new position in shares of Halozyme Therapeutics in the second quarter valued at about $214,504,000. William Blair Investment Management LLC purchased a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at approximately $196,540,000. Congress Asset Management Co. raised its holdings in shares of Halozyme Therapeutics by 85.6% during the 3rd quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company’s stock worth $251,890,000 after acquiring an additional 1,052,509 shares during the period. Royal London Asset Management Ltd. lifted its position in Halozyme Therapeutics by 12.4% in the second quarter. Royal London Asset Management Ltd. now owns 1,810,815 shares of the biopharmaceutical company’s stock valued at $141,732,000 after acquiring an additional 200,262 shares during the last quarter. Finally, First Trust Advisors LP grew its holdings in shares of Halozyme Therapeutics by 46.5% during the first quarter. First Trust Advisors LP now owns 1,482,340 shares of the biopharmaceutical company’s stock worth $95,804,000 after buying an additional 470,558 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Q3 revenue rose 39% year over year to $493 million and adjusted EPS of $2.39 beat estimates. Record royalty revenue increased 44% to $341 million. Halozyme also raised its 2026 revenue, royalty, EBITDA and adjusted EPS guidance. Q3 results and guidance
• Positive Sentiment: The FDA approved Johnson & Johnson’s RYBREVANT FASPRO, which uses Halozyme’s ENHANZE technology, for certain patients with advanced head and neck cancer. The expanded use could support future royalties. FDA approval
• Positive Sentiment: Halozyme said its analysis of Medicare’s drug-price negotiation rule indicates zero to minimal impact on royalty revenue through at least 2035, easing a potential long-term concern. Medicare rule assessment
• Neutral Sentiment: Citizens JMP raised its price target to $149 and maintained an outperform rating, while Wells Fargo raised its target to $110 but kept an equal-weight rating—signaling differing views on further upside. Citizens JMP rating
• Negative Sentiment: Despite the earnings beat and higher guidance, reports noted a negative share reaction and questions around the guidance reset, suggesting results may not have met elevated investor expectations. The Merck patent dispute also remains an investor focus. Earnings reaction and guidance questions

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.

Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.